Skip to main content
. 2019 Nov 6;13(2):293–300. doi: 10.1111/cts.12709

Figure 1.

Figure 1

Incidence of SOS after hematopoietic stem cell transplantation (HSCT) in patients receiving busulfan‐based myeloablative conditioning. (a) cumulative incidence of sinusoidal obstruction syndrome (SOS; 95% confidence interval). (b) Incidence of SOS depending on year of HSCT. *Stop of norethisterone therapy + individualized dosing guided by busulfan (Bu) blood concentration. **Introduction of ursodiol. ***Introduction of N‐acetyl‐L‐cysteine during Bu.